Finished-dose manufacturers represent 72.0% within the buyer type segment and direct supply accounts for 68.0% of the sales channel category in 2026. The aripiprazole market is estimated at USD 56.86 million in 2026, is projected to reach USD 89.99 million by 2036 and is forecast to post a 4.70% CAGR between 2026 and 2036.